Alnylam Pharma (ALNY) Tops Q2 EPS by 30c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Alnylam Pharmaceuticals (ALNY) PT Raised to $193 at Stifel Following Results
August 3, 2021 10:51 AM EDTStifel analyst Paul Matteis raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $193.00 (from $178.00) while maintaining a Buy rating following Q2 results.
The analyst commented, "We are reiterating our Buy rating and we're raising our numbers and target price on 2Q beats,... More
